Jacques Azzi is an Oncology physician affiliated with Mount Sinai Hospital. OpenAlex indexes 49 publications with 685 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 100296030
Telephone
212-241-6756Provider last certified this registry record 17 Jun 2021.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20256 payments
- Kite Pharma, Inc.Program year20259 payments
- SANOFI-AVENTIS U.S. LLCProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
45.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor45.8%Acyclovir100%Part D≥17 patientsAnti-infectives
20.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor7.5%Valacyclovir100%Part D<11 patientsShort-acting sulfonamides6.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
18.2%Thalidomide Analog10.7%Lenalidomide100%Part D<11 patientsLeukocyte Growth Factor7.5%Zarxio100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Outcomes from the Pooled Safety Analysis of CD19 Nex-T™ (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results from Phase 1 Breakfree Studies
Biology of Blood and Marrow Transplantation
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel J. Drucker
Mount Sinai Hospital
Karyn Goodman, MD
Mount Sinai Hospital
Edward Wolin, MD
Mount Sinai Hospital
Joshua Zeichner, MD
Mount Sinai Hospital
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”